Ketamine Therapy for Treatment-Resistant Depression and PTSD

The phone call that stays with me came from a middle‑aged father who had tried everything for his depression: multiple antidepressants, augmentation with lithium and atypical antipsychotics, cognitive behavioral therapy, and even a course of transcranial magnetic stimulation. He still woke every morning under the weight of a concrete slab. Suicidal thinking would crest by afternoon. What changed the trajectory, at least enough to catch a foothold, was a series of ketamine infusions paired with careful preparation and focused psychotherapy in between. The infusions did not “cure” him. They did open a window wide enough for skills, connection, and meaning to get back in.

That pattern, fast relief followed by the work of consolidation, is what clinicians see repeatedly with ketamine therapy for treatment‑resistant depression and PTSD. The drug is not a silver bullet, but for a subset of people it is the first intervention in years that genuinely moves the needle.

What we mean by treatment‑resistant

Treatment resistance in depression typically refers to inadequate response after at least two trials of antidepressants at therapeutic doses for adequate periods, often combined with psychotherapy. In practice, many patients have tried far more by the time ketamine enters the conversation. The numbers are sobering. Up to a third of people with major depression do not achieve remission despite stepping through two, three, or more medication classes. In PTSD, entrenched patterns of hyperarousal, avoidance, and negative beliefs can blunt the effect of trauma therapy when the nervous system feels stuck in survival mode.

Failure to respond does not mean failure to heal. In resistant cases, we look for interventions that change how the brain can learn, not just how it feels in the moment. Ketamine’s value lives in that space.

Why ketamine changed the conversation

Ketamine is an NMDA receptor antagonist with downstream effects on glutamate signaling and neuroplasticity. In plain terms, it briefly shifts how neurons communicate, then ushers in a period when the brain seems more able to form and prune connections. This “plasticity window” is not abstract biochemistry to people in the chair. It often shows up as loosened cognitive loops, softened rigidity, and a surprising capacity to consider different stories about the self.

Several details matter clinically:

Onset is fast. Many patients notice relief of depressive intensity or suicidal ideation within hours, peaking over one to three days. Effects are robust in a meaningful minority. Response rates for treatment‑resistant depression commonly land between 50 and 70 percent after a short series, though remission rates are lower and durability varies. The drug experience is unusual. Dissociation, shifts in time perception, and vivid imagery are common during dosing, typically lasting 30 to 90 minutes.

The compound used in clinics is most often racemic ketamine, delivered intravenously or intramuscularly, and occasionally sublingually. Esketamine, the S‑enantiomer, is FDA‑approved as a nasal spray for treatment‑resistant depression and for depressive symptoms with acute suicidal ideation or behavior. Esketamine must be administered in a certified clinic with observation because of blood pressure and dissociation risks.

What the evidence supports now, and what still needs study

For major depression that has resisted standard care, the evidence base is substantial enough to guide practice. Multiple randomized trials and meta‑analyses show rapid antidepressant effects from ketamine, often after the first or second treatment, with cumulative gains over a short series. The benefit tends to wane over days to weeks without maintenance. Some patients maintain improvement with less frequent booster sessions; others do not sustain response despite every best effort.

For suicidality, the picture is clearer. Reduction in suicidal thinking can be significant within 24 hours, independent of mood change, which has important implications for crisis stabilization. That said, this is not a substitute for safety planning, close follow‑up, or hospitalization when indicated.

PTSD data are promising but more mixed. Small randomized studies show symptom improvement after repeated dosing, particularly when ketamine is paired with structured psychotherapy focused on trauma processing and reconsolidation. Clinically, the strongest PTSD gains I have seen come when ketamine reduces avoidance and hyperarousal enough to allow trauma therapy to land. EMDR therapy, written narrative exposure, and cognitive processing work can move faster, and often with less overwhelm, when the nervous system is more flexible.

What a course of ketamine therapy looks like

Protocols vary across clinics, but the pattern is recognizable. For IV ketamine, a common starting dose is 0.5 mg per kg infused over about 40 minutes. Some patients need less, some more, titrated based on effect and tolerability. A typical induction involves six to eight sessions over two to four weeks, with close monitoring of blood pressure, dissociation intensity, nausea, and overall mental state. Intramuscular dosing achieves a similar arc through a different kinetic curve. Esketamine is delivered intranasally at standardized doses under a Risk Evaluation and Mitigation Strategy program, with a two‑hour observation period after each session.

I tell patients to expect three phases around each dose. The first is set and setting, the half hour before, when we review intention, adjust the environment, and align on safety signals. The second is the acute experience itself, often eyes closed and with instrumental music, during which the internal landscape can become quite vivid or expansive. The third is reentry and immediate integration, the hour after, when impressions are put to words and images into meaning. The work between sessions can be just as important as the drug day.

Day‑to‑day practicalities matter. Patients should not drive the day of treatment. Blood pressure is checked repeatedly, and food is withheld for several hours beforehand to reduce nausea. Someone needs to escort the patient home. Side effects are usually short‑lived: dizziness, nausea, headache, and a feeling of disconnection that fades within two hours. Transient increases in blood pressure are common and generally manageable with monitoring.

Who is a good candidate, and who should pause

The person most likely to benefit is not defined only by diagnosis, but by readiness to engage the opening ketamine can create. Candidates often include people with major depressive disorder that has not responded to antidepressants, or PTSD that remains highly symptomatic despite a reasonable trial of trauma‑focused psychotherapy. Comorbid anxiety is frequent and does not preclude benefit. Chronic pain can sometimes improve when central sensitization has a mood component.

The flip side is just as important. Certain clinical pictures raise caution or push us to look elsewhere first.

Bipolar I disorder with a history of mania or rapid cycling, particularly if mood stabilizers are not firmly onboard. Active psychosis, or a primary psychotic disorder, where dissociation risks worsening paranoia or disorganization. Uncontrolled hypertension, unstable cardiac disease, or severe obstructive sleep apnea that is not treated. Pregnancy or breastfeeding, where data are limited and risks are not fully characterized. Significant substance use disorder, especially with history of ketamine misuse, unless safeguards and addiction treatment are in place.

These are not hard walls in every case, but they call for specialist input, additional medical clearance, or an alternate plan.

The felt experience, and why set and setting change outcomes

When people describe their sessions, certain themes recur. A software engineer heard his self‑criticism reduce to background noise as if the volume knob were turned down. A teacher watched a repeating loop of a childhood scene, then noticed the loop had a door she could open. Another patient, a Marine veteran, felt his body soften for the first time in months while listening to cello suites. These are not mystical reports so much as real‑world demonstrations of state change. The brain generates different possibilities when fear and default narratives loosen their grip.

Environment is not a luxury. Dim light, eyeshades to reduce distraction, carefully chosen non‑lyrical music, and a therapist or guide skilled at tracking breath and facial expression all contribute. Preparation reduces surprises. Patients learn that waves of intensity crest and recede, that grounding is available through breath or touchstones, that imagery can be observed rather than believed. Intention setting is not a wish list, more a compass. A simple phrase such as “let me see this differently” is often enough.

Safety, side effects, and what we watch closely

In medical settings with proper screening and monitoring, ketamine has a favorable safety profile. Blood pressure and heart rate rise briefly, then settle. Nausea affects roughly 10 to 20 percent, manageable with antiemetics. Dissociation is expected and in most cases therapeutic when well framed. Emergence reactions, including anxiety or tearfulness, are best handled with calm presence and time rather than abrupt pharmacologic suppression.

Two rare but important risks deserve mention. First, bladder inflammation has been reported in heavy recreational use, often daily or near daily, at high doses. At therapeutic frequencies and doses, this appears uncommon, but we ask about urinary symptoms across longer maintenance courses. Second, there is a nonzero addiction risk. People with opioid or stimulant use disorders sometimes find ketamine’s relief seductive. Safeguards include structured dosing, no at‑home supply without good reason, and integrated addiction care when relevant.

Mania can be precipitated in susceptible individuals. That is why we screen for bipolar spectrum illness and optimize mood stabilizers first. Psychosis is a red flag. If a patient becomes paranoid or disorganized during lower doses, we step back and reassess fit.

Medical and legal guardrails

Esketamine is the only form approved by the FDA for treatment‑resistant depression and depressive symptoms with suicidality. It must be given in a certified clinic with observation, and insurance coverage is more common for this pathway. Racemic ketamine infusions and intramuscular injections for depression and PTSD are off‑label but widely used, supported by a substantial and growing literature. Sublingual lozenges at home are also off‑label and sit at the far end of the risk spectrum. They have a place in maintenance for carefully selected, well‑stabilized patients under tight oversight, but they should not be anyone’s entry point.

The legal status of psychedelic‑assisted therapies is evolving by jurisdiction, but ketamine itself is a Schedule III medication available to prescribers. That availability places a burden on clinics to self‑regulate with thoughtful protocols, medical supervision, and integration of psychotherapy rather than acting as a volume dosing mill.

Cost, access, and the equity problem

Access is uneven. Esketamine sessions in the United States are often covered, but copays and deductibles can still accumulate. Racemic ketamine infusions typically run 300 to 800 dollars per session out of pocket, sometimes more in large coastal cities. A full induction series can exceed 2,000 to 4,000 dollars, not including therapy time. Some clinics bundle psychotherapy, which is good for care but can price people out. Geographic deserts are real too. Rural areas may have no ketamine providers within hours of driving.

Informed decisions require frank conversations about cost, expected benefit, and alternatives. If finances are tight, we prioritize a shorter pilot series to gauge response before committing, and we fold in lower‑cost integration supports like group therapy, peer support, or guided self‑practice where appropriate.

Making ketamine part of a broader healing plan

Ketamine is a lever. The direction you push matters. For depression, we often pair dosing with behavioral activation, compassion‑focused work, and targeted cognitive restructuring. For PTSD, the pairing matters even more.

EMDR therapy can be particularly powerful in the days after a ketamine session. Bilateral stimulation seems to meet a nervous system already in a state more capable of reconsolidation. People who previously flooded or shut down during EMDR can sometimes move through a memory channel with more steadiness. Similarly, cognitive processing therapy can use the post‑ketamine window to challenge stuck points and install alternative beliefs. Somatic trauma therapy modalities, including titrated exposure to bodily cues and gentle breathwork, land more easily when hyperarousal is dialed down.

For couples therapy, the role is indirect but meaningful. Depressive withdrawal or PTSD reactivity often strains partnerships. When ketamine reduces baseline threat, couples can learn to co‑regulate rather than escalate. A brief example: a couple in their thirties where one partner carried combat trauma had patterns of blame‑withdraw, then pursuit‑shutdown. After two weeks of ketamine‑assisted work focused on safety and naming states, they were able to pause in the heat of an argument and label, “I feel the rush,” then reach rather than retreat. The drug did not give them that skill. It opened a window where the skill could take root.

A patient day, seen through the clinic’s eyes

Sarah, a composite drawn from several patients to protect privacy, arrived for her fourth infusion after ten years of on‑and‑off major depression and a traumatic breakup that still echoed. Our plan that day included an intention to meet the belief, “I am unlovable,” from a soft distance. Her preparation included two EMDR sessions earlier that week where the target memory network had felt too hot to touch for more than a minute.

The infusion itself was uneventful medically. Her blood pressure rose modestly and settled within half an hour. About 20 minutes in, she described floating above a scene of her childhood bedroom, noticing familiar posters and the texture of carpet. It carried sadness, but not panic. She saw the younger self turn toward her and ask a question she had heard in therapy, “Is it my fault?” Then, in Sarah’s words, she felt an answer in her body rather than only thinking it, “No, you were a kid.”

Two days later, during EMDR therapy, the same scene came back with less charge. They were able to keep bilateral stimulation running for several sets without shutting down. Her score on a simple depressive symptom scale dropped from severe to moderate. She texted that she cleaned the kitchen for the first time in weeks. None of that is a miracle. It is what happens when state change meets structured processing and practical action.

Preparing for success

The period before starting therapy is an opportunity to stack the deck. Sleep steadiness is underrated. Hydration and nutrition matter. People who fall into a brief hypomanic‑like buzz after sessions often benefit from planned guardrails, like limiting device use and scheduling a quiet walk with a trusted friend instead. Alcohol and cannabis muddy signals and are best minimized or paused during the induction series. On therapy days, loose clothing, layers, and a plan for warmth help the body feel safe.

When patients ask how to “make it work,” my answer is not a hack. It is to treat the series like a short training camp. Bundle distress tolerance skills from therapy, gentle movement, and at least one hour of reflective time the day after a dose for journaling or guided inquiry. Small, repeatable actions beat grand plans.

Questions to ask a ketamine clinic before you start

How do you coordinate with my existing therapist or provide in‑house psychotherapy around dosing? What is your typical protocol for induction and maintenance, and how do you decide dosing? How do you screen for bipolar spectrum illness, psychosis risk, and cardiovascular issues? What happens if I have intense anxiety or distress during a session, and who will be with me? How do you track outcomes, side effects, and long‑term plans if the first series helps?

Straight answers here reveal a lot about a clinic’s philosophy. If the model is medication alone, with little attention to integration, your odds of durable change fall.

When ketamine is not enough, or not the right move

Sometimes the response is partial or absent. If three to four sessions produce no movement in mood or function, we pause and reassess. For depression, alternatives include another antidepressant class if any have been under‑tried, augmentation strategies with lithium or thyroid hormone, structured psychotherapy intensives, TMS, and in severe or psychotic depression, electroconvulsive therapy. For PTSD, a renewed look at trauma therapy fit is crucial. EMDR therapy feels like a mismatch for some people, while others find written exposure tolerable but imaginal exposure overwhelming, or vice versa. Somatic and parts‑based approaches can reach people who have limited access to explicit memory. PTSD therapy is not one thing; the right match matters as much as persistence.

Part of the judgment call involves life context. If domestic instability, active substance use, or medical illness is driving symptom recurrence, all the ketamine in the world will not fix it. Stabilizing the foundation is the therapeutic move.

Practical boundaries and maintenance

Maintenance schedules are individualized and should not be reflexive. Some patients do well with no further dosing for months after a successful induction paired with therapy. Others benefit from https://www.canyonpassages.com/trauma-therapy a taper to once every two to four weeks, then less frequently, always in concert with psychotherapy and lifestyle pillars. If the interval shortens progressively to chase relief, that is a signal to stop and reconsider the plan.

Bladder health monitoring is simple and worthwhile over longer courses. Periodic blood pressure checks and, for some, basic lab work maintain a safety net. Above all, we anchor to function rather than only symptom scales. Are you showing up at work more consistently? Reconnecting with friends? Sleeping on a schedule more days than not? These markers guide decisions better than chasing a particular number on a questionnaire.

Integrating learning into daily life

Ketamine’s window is real but brief. Turning state change into trait change takes practice. Patients who build routines around the post‑dose days tend to cement gains. A common pattern looks like this: therapy within 24 to 72 hours after a session, gentle aerobic activity to signal safety to the body, 15 minutes of writing or art to bring imagery into form, and one deliberately pleasant social contact to recruit reward circuitry. None of these are unique to ketamine. They are effective because the brain is listening more closely.

Partners can help too. In couples therapy, learning to name nervous system states in real time turns reactivity into information. Ketamine does not replace that work, but it can lower the threshold enough that strategies like time‑outs, repair attempts, and gratitude rituals actually get used. Trauma therapy benefits when home practice is practical and brief, such as one soothing image rehearsal at bedtime rather than a heroic 45‑minute protocol that no one can sustain under stress.

Choosing wisely, with clear eyes

Hope is appropriate. So is caution. Ketamine therapy has shifted what is possible for many people living with treatment‑resistant depression and PTSD. The best outcomes I have seen share a pattern: careful medical screening, a clear therapeutic container, collaboration with a skilled therapist, and honest tracking of what changes in daily life. When those pieces align, ketamine is not a detour from good care. It is a way to create traction where there has been far too little for far too long.